title: The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival.
abstract: OBJECTIVE
  In the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancer patients and also prognostic factors related with recurrence-free survival (RFS) in recurrent patients.
  
  
  METHODS
  We evaluated retrospectively 1980 breast cancer patients. Relapsed was defined as early if it was occured first 5 year of follow-up (Group 1) and late if it was occured after 5 years (Group 2). The clinicopathological factors were compared in respect of time of recurrence. The prognostic factors were evaluated using univariate and multivariate analyses.
  
  
  RESULTS
  Recurrence wase detected in 141 patient during follow-up. Tumors recurred after 5 years more likely to have lower stage (p = 0.05), tumors without lymphovascular invasion (LVI) (p < 0.001) and perineural invasion (PNI) (p = 0.01), and also HER2 negative (p < 0.001). The median RFS time and 5 years RFS rates were 42.9 months and 31.9 %, respectively. LVI (p = 0.01), PNI (p = 0.03), HER2 (p = 0.003), progesterone receptor (PR) (p = 0.04), the presence of neoadjuvant chemotherapy (p = 0.003), adjuvant hormonotherapy (p = 0.05) were found to be related with RFS. Axillary lymph node metastasis (p = 0.05) and the presence of PNI (p = 0.009) were poor prognostic factors for early recurrent group. PR-positive tumors (p = 0.001) and luminal subtypes (p = 0.03) had instances of late recurrences significantly.
  
  
  CONCLUSIONS
  Clinicopathological factors predicting the recurrence time in breast cancer were important to modify adjuvant therapy.
authors.affiliation: Department of Medical Oncology, HaydarpasaNumuneEducation and Research Hospital, Selimiye Mah, Şair Nesimi sok, Kardeşler Apt., No: 1, Daire: 4, Uskudar, 34668, Istanbul, Turkey. basakoven@yahoo.com.
authors.forename: B B
authors.initials: BB
authors.lastname: Oven Ustaalioglu
authors.affiliation: Department of Medical Oncology, Dr. LutfiKirdarKartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: O
authors.initials: O
authors.lastname: Balvan
authors.affiliation: Department of Medical Oncology, Medipol University, Istanbul, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Bilici
authors.affiliation: Department of Medical Oncology, Dr. LutfiKirdarKartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Develi
authors.affiliation: Department of Medical Oncology, Dr. LutfiKirdarKartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Aliustaoglu
authors.affiliation: Department of Pathology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.
authors.forename: F A
authors.initials: FA
authors.lastname: Vardar
authors.affiliation: Department of Medical Oncology, HaydarpasaNumuneEducation and Research Hospital, Selimiye Mah, Şair Nesimi sok, Kardeşler Apt., No: 1, Daire: 4, Uskudar, 34668, Istanbul, Turkey.
authors.forename: B
authors.initials: B
authors.lastname: Erkol
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D011379:Prognosis; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: Breast cancer; Late recurrence; Recurrence; Recurrence-free survival